In recent days, my site was unreachable because I worked on multilingualism. The essential steps are done. There are still some details to work on, but this does not interfere with navigation. I hope thus to promote the international exchange and get more range outside Germany.
This post is currently not available in English, because it is related exclusively to the German drug market.
Today I want to once again report from the 51st Congress of the American College of Neuropsychopharmacology (ACNP), 2nd – 6th December 2012 in Hollywood, Florida, even though the Congress has already ended. The study was presented as a poster, but I believe it could have been also presented in the “Highlights” session, in which unfortunately the preclinical work dominated (see my last posting dated 12/04/2012).
At least in Germany, acetylcholinesterase inhibitors still have the reputation of being of dubious benefit in patients with dementia of the Alzheimer’s type. It is widely believed that their effect is limited and is in no way proportionate to the adverse effects and costs.
At the 51st Congress of the American College of Neuropsychopharmacology (ACNP), 2nd – 6th December 2012 in Hollywood, Florida, in the first of three poster sessions 214 posters were presented. It was alarmingly difficult, yet to find posters, which did not report on animal studies, but had obtained clinical, human data. About two-thirds of the posters reported on animal experimental data. Continue reading
At the 51st Congress of the American College of Neuropsychopharmacology (ACNP), 2nd – 6th December 2012 in Hollywood, Florida, Carolyn I. Rodriguez and colleagues from Columbia University in New York reported yesterday the results of a small pilot study on the use of ketamine in obsessive-compulsive disorder (OCD). The very rapid antidepressant effects of the NMDA receptor antagonist ketamine in depressive disorders – especially in treatment-resistant patients – has been shown in numerous studies. This applies to both uni- and bipolar depression. A small open case series recently presented also suggests an effect of ketamine in OCD. Continue reading
At the 51st Congress of the American College of Neuropsychopharmacology (ACNP), 2nd – 6th December 2012 in Hollywood, Florida, Eric Finzi and Norman Rosenthal from Chevy Chase Cosmetic Center in Chevy Chase, Maryland, reported today at the “Hot Topics” session on the results of their double-blind, placebo-controlled study of botulinum toxin A in patients with depression. Charles Darwin suggested that a person’s mood is not necessarily reflected in its facial expression, but that, conversely, the latter can have effects on mood and emotion. This hypothesis was later expanded by the American psychologist William James to the “facial feedback hypothesis”. It was again Darwin, who described that depressed people suffer from an over-activity of the corrugator (musculus corrugator supercilii, the “front-or brow corrugator”). Injection of botulinum toxin into the Glabella region (the region above the root of the nose) leads to effective paralysis of the muscle for about three months.
Finzi included patients with a depressive disorder into his study. Continue reading